FREDUN vs NEPHROPLUS: Stock Comparison
FREDUN PHARMACEUTICALS L shows a lower P/E and a higher dividend yield, while NEPHROCARE HEALTH SERV L shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
FREDUN leads 6; NEPHROPLUS leads 1 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | FREDUN | NEPHROPLUS |
|---|---|---|
| Live Price | ₹1,279.2 | ₹738 |
| Day Change | 4.72% | 0.38% |
| Volume | 97,836 | 17,250 |
| 52-Week High | ₹1,590 | ₹781.5 |
| 52-Week Low | ₹1,195.2 | ₹446 |
| Distance from 52W High | -19.55% | -5.57% |
Valuation
| Metric | FREDUN | NEPHROPLUS |
|---|---|---|
| Market Cap | ₹0 Cr | ₹7,398 Cr |
| P/E Ratio | 0x | 96.91x |
| P/B Ratio | 0x | 6.67x |
| EPS | ₹7.94 | ₹1.25 |
| Book Value | ₹168.16 | ₹111.27 |
| Dividend Yield | 0.11% | 0% |
Growth
| Metric | FREDUN | NEPHROPLUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | -39.53% |
| Qtr Profit Growth | -0.27% | -60.71% |
Profitability & Leverage
| Metric | FREDUN | NEPHROPLUS |
|---|---|---|
| ROE | — | 10.88% |
| ROCE | — | 13.58% |
| Net Margin | 0% | 7.69% |
| Operating Margin | — | 14.87% |
| Debt to Equity | — | 0.07x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | FREDUN | NEPHROPLUS |
|---|---|---|
| Promoter Holding | 44.57%▲ 0.4 pp | 21.07% |
| FII Holding | 1.06% | 8.78%▼ 1.16 pp |
| DII Holding | 2.94%▲ 0.11 pp | 9.05%▲ 0.4 pp |
| Public Holding | 51.43%▼ 0.51 pp | 18.32%▲ 0.76 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FREDUN PHARMACEUTICALS L and NEPHROCARE HEALTH SERV L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.